Taiwan
· Delayed Price · Currency is TWD Mycenax Biotech Company Description
Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States.
The company develops monoclonal antibodies, bi-specific antibodies, fc-fusion proteins, recombinant proteins, peptides, protein conjugates (non-toxin), antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), as well as plasmids and DNA vaccines.
It also provides process development solutions, including development of production cell lines, upstream and downstream process development, process scale-up, formulation development, and analytical methods; in-house analytical services; GMP manufacturing services, such as drug substance and products manufacturing, and cell banking; and manufacturing technologies.
The company was founded in 2001 and is headquartered in Zhubei, Taiwan.
| Country | Taiwan |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 387 |
| CEO | Pei-Jiun Chen |
Contact Details
Address: No. 66, Shengyi 2nd Road Zhubei, 302041 Taiwan | |
| Phone | 886 3 667 0880 |
| Website | mycenax.com.tw |
Stock Details
| Ticker Symbol | 4726 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0004726005 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Pei-Jiun Chen | President Chief Executive Officer and Chairman |
| Chin-Hao Liang | Associate Vice President of Administration and Management Division |
| Wei-I Chou | Associate Vice President of Pharmaceutical Development Division |
| Liru Yeh | Corporate Governance Officer |